Use the hyperlinks, where available to access additional clinical trial information.
An Open-label, Multicenter, Phase I Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
This trial has three parts, and is seeking to learn more about RO7444973 in people with unresectable and/or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive, solid cancers, carrying the HLA-A*02:01 allele. In Part I (Single Participant Cohort Dose Expansion), RO7444973 is administered intravenously (IV) every 3 weeks (Q3W) at a fixed dose in a single participant per dose level. In Part II (Multiple Participant Cohort Dose Escalation), RO7444973 is administered IV Q3W at a fixed dose in multiple participants per dose level. Step-up dosing may also be explored. In Part III (Recommended Phase 2 Dose Expansion), a recommended phase 2 dose and dosing regimen will be further investigated. In all parts, Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants >/= 30 kg or at 12 mg/kg for participants < 30="">